Sarrin Chethik

35 posts

Sarrin Chethik

Sarrin Chethik

@schethik

@UChi_MSA Views are my own

Washington, DC Katılım Ekim 2015
167 Takip Edilen45 Takipçiler
Sarrin Chethik
Sarrin Chethik@schethik·
@audowla @CGDev @audowla pull funding refers to any outcome-based funding including advance market commitments and prizes. AMCs would be great (pay based on discovery and adoption), but prizes would be useful too (pay just based on discovery)!
English
1
0
0
12
Asif Dowla
Asif Dowla@audowla·
@CGDev @schethik The pull funding sounds like the Advanced Market Commitment, a la Cremer. What is the difference?
English
1
0
0
41
Sarrin Chethik
Sarrin Chethik@schethik·
(I understand there's nuance -- fixed costs for setting up a pull fund, concerns about gaming, etc. -- but I still think pull funding may be under-used)
English
0
0
2
36
Sarrin Chethik
Sarrin Chethik@schethik·
Companies currently use bug bounties to catch the bugs their software engineers didn't find. Why not use a similar approach for public goods?
English
1
0
2
51
Sarrin Chethik
Sarrin Chethik@schethik·
An implicit argument in some of my recent blog posts: funders often pick between grants and prizes, but why not use both? Fund the teams you believe in. But (might as well) promise to pay someone else if they solve a problem first or better.
Center for Global Development@CGDev

What if we paid for results, not just research? With NIH funding under pressure, @schethik makes the case for “pull” funding to complement existing grants and unlock overlooked treatments like repurposed drugs. cgdev.org/blog/case-pull…

English
1
0
3
113
Wall Street Journal Opinion
Wall Street Journal Opinion@WSJopinion·
You can teach an old drug new tricks. Aspirin prevents heart attacks, and good policy could give other generic drugs a second life, write Christopher Snyder and Sarrin Chethik on.wsj.com/4uKUSS7
English
1
3
9
6.7K
Sarrin Chethik
Sarrin Chethik@schethik·
Also, for those w thoughts, the FDA just announced an RFI on the topic and mentions collaborations with NIH and CMS. Exciting times! fda.gov/news-events/pr…
English
0
0
1
56
Sarrin Chethik
Sarrin Chethik@schethik·
There's real momentum building around generic drug repurposing. However, the policy response could be minimal (one or two ad hoc approvals) or broad-based and durable (long-term incentives for development). Chris and I discuss the latter. Gift link below
Wall Street Journal Opinion@WSJopinion

You can teach an old drug new tricks. Aspirin prevents heart attacks, and good policy could give other generic drugs a second life, write Christopher Snyder and Sarrin Chethik on.wsj.com/4uKUSS7

English
1
6
7
3.1K
Sarrin Chethik retweetledi
Coefficient Giving
Coefficient Giving@coeff_giving·
Promising treatments for some of the world's most neglected diseases may already exist. But because generic medicines cannot be patent-protected, there is little incentive to test them for new uses. To support generic drug repurposing, we’re launching an RFP: a quick 🧵
English
2
12
48
5.1K
Sarrin Chethik retweetledi
Caleb Watney
Caleb Watney@calebwatney·
@binarybits Support a focused research organization! Fund a cool clinical trial! Buy out a patent! Expand emergent ventures to a new part of the world! Plenty of options
Washington, DC 🇺🇸 English
2
1
45
1.3K
Sarrin Chethik
Sarrin Chethik@schethik·
Life-saving breakthroughs can come from repurposing existing (generic) drugs, but there's almost no incentive to do so. Grateful to join a thoughtful @Freakonomics discussion on the promise of generic drug repurposing and how innovative funding tools can unlock its potential
Freakonomics@Freakonomics

Using an old drug in a brand new way can save patients’ lives. So why aren’t companies doing it? Because as it turns out, “repurposing” an existing drug has 0 financial upside. In this episode, guest host Steve Levitt explores what happens when markets fail patients, along with physician-scientist David Fajgenbaum (whose life was saved by a decades-old drug used in a new way) and economist Chris Snyder. How do you fix a market that doesn’t pay for cures? This new episode of Freakonomics Radio is available now, wherever you get your podcasts. link.podtrac.com/cwk3g7eb

English
0
3
6
478
Sarrin Chethik retweetledi
Market Shaping Accelerator (MSA)
Market Shaping Accelerator (MSA)@UChi_MSA·
New G20 High Level Independent Panel  on pandemic preparedness out. Recommendation 3: Enabling at-risk financing for low and middle income countries to crucial to ensuring low and middle income countries get the vaccines and therapeutics they need during the next outbreak
English
2
3
4
1.1K
Sarrin Chethik
Sarrin Chethik@schethik·
7/ Motivated people/orgs surfacing insights from obs data seems useful, but to fully take advantage of this info we need serious funding and smart funding approaches
English
0
0
1
93
Sarrin Chethik
Sarrin Chethik@schethik·
6/ This seems tractable given that the recent MAHA strategy report already highlights drug repurposing and similar approaches as major opportunities
Sarrin Chethik tweet media
English
1
0
1
101
Sarrin Chethik
Sarrin Chethik@schethik·
1/ Great post on mining Reddit to inform treatment ideas. Lots of promising treatments never get tested bc trials are exp + lacking IP protections. However, this problem is too large for a few altruistic people/orgs to tackle. Instead, we need govt $ to focus on the following 🧵
Patrick Collison@patrickc

Observing some people close to me with chronic health conditions, it's striking how useful Reddit frequently ends up being. I think a core reason is because trials aren’t run for a lot of things, and Reddit provides a kind of emergent intelligence that sits between that which any

English
1
1
3
660

Keşfet

@audowla @CGDev @WSJopinion @binarybits @Freakonomics @elonmusk @BarackObama @taylorswift13